Medicare has never covered Wegovy for weight loss through the standard Part D drug benefit — federal law specifically excludes anti-obesity medications from that benefit. The Medicare GLP-1 Bridge program, live since July 1, 2026, doesn't change that underlying law. Instead, it builds a separate, temporary pathway around it: a flat $50 copay for a small list of GLP-1 drugs, funded and administered outside your normal Part D plan.
That structure is exactly why so many beneficiaries find this confusing. You're still a Part D member. Your card still says Part D. But the Wegovy prescription you're filling under the Bridge isn't processed the way your other Part D drugs are, doesn't count toward the same spending cap, and follows a completely different approval path. This guide walks through what that actually means for your application, your wallet, and your pharmacy visit.
What the Medicare GLP-1 Bridge Program Covers
The Medicare GLP-1 Bridge is a temporary demonstration program created by the Centers for Medicare & Medicaid Services (CMS). It launched July 1, 2026, and is scheduled to run through December 31, 2027 — an 18-month window intended to give beneficiaries earlier access to GLP-1 weight-loss medications while CMS continues developing a longer-term coverage model.
| Medication | Manufacturer | Covered Under the Bridge? |
|---|---|---|
| Wegovy (semaglutide) — injection and tablets | Novo Nordisk | Yes |
| Zepbound (tirzepatide) — KwikPen only | Eli Lilly | Yes |
| Foundayo (orforglipron) — oral tablet | Eli Lilly | Yes |
| Ozempic (semaglutide) — diabetes indication | Novo Nordisk | No — not FDA-approved for weight management |
| Mounjaro (tirzepatide) — diabetes indication | Eli Lilly | No — covered separately under standard Part D for diabetes |
An estimated 3.8 million Medicare beneficiaries could meet the program's basic clinical criteria, according to a KFF analysis of Part D enrollment data. That scale is the point: this program exists specifically because the standard Part D exclusion for weight-loss drugs left a very large group of beneficiaries with no affordable path to these medications.
Wegovy Under the Bridge vs Wegovy Under Standard Part D
Wegovy holds two separate FDA approvals, and which one applies to your prescription determines which coverage lane you're in. This distinction causes more confusion in Medicare forums than almost anything else related to this program.
| Why Wegovy Is Prescribed | Coverage Lane | Counts Toward Part D Cap? |
|---|---|---|
| Chronic weight management (weight loss) | Medicare GLP-1 Bridge — $50 flat copay | No |
| Reducing risk of major cardiovascular events in adults with established heart disease who are obese or overweight | Standard Medicare Part D, if your plan's formulary covers it | Yes |
This distinction is not optional or a matter of preference. CMS has stated that beneficiaries whose GLP-1 use is already coverable under the standard Part D benefit — including Wegovy prescribed for cardiovascular risk reduction in adults with established heart disease — do not qualify for the Bridge program for that use. If that's your situation, your regular Part D plan, not the Bridge, is the correct pathway, and it's actually the better one financially, since standard Part D cost-sharing counts toward your annual out-of-pocket cap while the Bridge's $50 does not.
Eligibility Requirements for the $50 Copay
| Requirement | Detail |
|---|---|
| Medicare enrollment | Must be enrolled in a Medicare Part D plan — either a standalone prescription drug plan or a Medicare Advantage plan with drug coverage (MA-PD) |
| Body Mass Index (BMI) | BMI of 35 or higher, or BMI of 27 or higher with a qualifying weight-related condition |
| Qualifying comorbidities (if BMI 27–34.9) | Conditions such as hypertension, prediabetes, or cardiovascular disease |
| Prescribed purpose | Must be prescribed specifically for chronic weight management, not diabetes or an indication already covered under standard Part D |
| Prior authorization | Your prescriber must submit a PA request to the program's central claims processor — this cannot be self-submitted by the beneficiary |
Note on the clinical criteria: the specific BMI and comorbidity thresholds are set by CMS and administered through the prior authorization review, not determined by your individual Part D plan. Your plan does not review or approve Bridge prescriptions — the central processor does.
Bridge Program vs Standard Part D: Side-by-Side
| Feature | Medicare GLP-1 Bridge | Standard Medicare Part D |
|---|---|---|
| Who reviews the request | Program's designated central claims processor | Your specific Part D plan |
| Monthly cost if approved | Flat $50 for a 30-day supply | Varies by plan tier, deductible status, and coinsurance |
| Counts toward Part D deductible? | No | Yes |
| Counts toward the $2,100 annual OOP cap (2026)? | No | Yes |
| Extra Help (LIS) subsidy applies? | No | Yes, if you qualify |
| Covers weight-loss use of Wegovy? | Yes, if clinical criteria are met | No — excluded by federal law |
| Covers cardiovascular-risk-reduction use of Wegovy? | No — routed to standard Part D instead | Possibly, depending on your plan's formulary |
| Program end date | December 31, 2027 (temporary demonstration) | Ongoing, permanent benefit |
Step-by-Step: How to Apply
Talk to your prescriber about weight management with Wegovy
Your provider evaluates your overall health, weight history, and whether Wegovy specifically — rather than another treatment — is clinically appropriate for you.
Confirm your Medicare Part D enrollment
You must be actively enrolled in a Part D plan, whether standalone or bundled into a Medicare Advantage plan. The Bridge program has no pathway for beneficiaries without Part D coverage at all.
Confirm Wegovy is the right drug for the right reason
Make sure your prescriber documents that the prescription is for chronic weight management specifically — not diabetes and not cardiovascular risk reduction, which route through a different coverage pathway.
Your prescriber submits the prior authorization
This goes to the program's designated central claims processor, not to your regular Part D plan. Your provider's office handles this submission — there's no beneficiary-facing enrollment portal or form to complete yourself.
Wait for the eligibility and clinical review
The central processor checks your BMI and comorbidity documentation against the program's criteria. Processing times can vary, and this is a newer system many prescriber offices are still getting used to, so build in some buffer time before you expect to fill your first prescription.
Fill your prescription at a participating pharmacy
Pharmacies do not need to individually opt in to participate — the Bridge program's billing runs automatically through the designated processor once your PA is approved. You pay the $50 copay directly at the counter.
What Happens at the Pharmacy
Once your prior authorization is approved, filling the prescription itself is simple — the complexity lives entirely in the approval step, not the pickup.
- You do not need to switch pharmacies or use a specialty mail-order pharmacy specifically for this program.
- The pharmacy bills the program's central processor separately from your regular Part D claims for other medications.
- Your other prescriptions continue to run through your normal Part D plan exactly as before — the Bridge only affects the Wegovy claim.
- You pay $50 for a 30-day supply at the counter; there is no reimbursement process to file yourself.
- If your pharmacist says the claim isn't processing correctly, the most common cause is a prior authorization that hasn't yet been approved or finalized — not a pharmacy-side error.
Why the $50 Not Counting Toward Your Cap Matters
This is the tradeoff most explanations of the Bridge program skip past, and it matters most for beneficiaries who take other expensive medications.
Example: if you also take a specialty drug for a separate condition and are on track to hit the $2,100 Part D out-of-pocket cap for 2026 through that medication alone, your Wegovy Bridge copay doesn't help you get there faster — because it isn't part of the same benefit. You'll keep paying $50 a month for Wegovy even after you've hit your cap and started paying $0 for your other Part D drugs.
The flip side is also true: if you're a beneficiary with Extra Help (the Low-Income Subsidy) who normally pays very little for covered drugs, the Bridge's $50 copay does not receive that same subsidy reduction, since Extra Help only applies within the standard Part D benefit. For some beneficiaries with very limited incomes, KFF's analysis has flagged that even $50 a month may be a genuine barrier — a detail easy to miss in coverage of this program that focuses mainly on the headline savings compared to list price.
Decision Tree: Which Lane Applies to You?
Start Here
Why is Wegovy being prescribed for you?
You have established heart disease
Wegovy is being used to reduce cardiovascular event risk
Use Standard Part D
Check your plan's formulary and prior authorization requirements — this spending counts toward your OOP cap
BMI 35+, or 27+ with a qualifying condition
Wegovy is being prescribed specifically for weight loss
Pursue the GLP-1 Bridge
Ask your prescriber to submit a PA to the central processor for the $50 copay
Real-World Examples
| Detail | Outcome |
|---|---|
| Situation | 68-year-old Part D beneficiary, BMI 37, no established heart disease, prescribed Wegovy for weight management |
| Process | Prescriber submitted PA documenting BMI and clinical rationale directly to the central processor |
| Result | Approved within the program's standard review window; $50 copay confirmed at pharmacy pickup |
| Detail | Outcome |
|---|---|
| Situation | 72-year-old beneficiary with established coronary artery disease, overweight, prescribed Wegovy for cardiovascular risk reduction |
| Process | Initial Bridge PA request was declined because the prescribed use was already coverable under standard Part D |
| Result | Prescriber resubmitted through the beneficiary's regular Part D plan instead; approved there, with cost-sharing counting toward the annual cap |
| Detail | Outcome |
|---|---|
| Situation | Beneficiary receiving Extra Help, normally pays $4.50–$11.20 for covered generics and brands under standard Part D |
| Consideration | The Bridge's flat $50 copay is higher than this beneficiary's usual Extra Help cost-sharing for other drugs, since Extra Help doesn't apply to the Bridge |
| Result | Beneficiary proceeded with the Bridge after confirming $50/month was still affordable and far below Wegovy's list price, but budgeted for it as a separate, fixed monthly cost outside their usual drug spending pattern |
What Happens After December 31, 2027
The Bridge program was designed as a stopgap — a temporary measure ahead of a longer-term Medicare model for GLP-1 coverage, often referred to as the BALANCE Model. That longer-term model has already seen parts of its planned rollout delayed, which means beneficiaries currently relying on the Bridge shouldn't assume $50 pricing continues automatically once the demonstration period ends.
If you start Wegovy through the Bridge program now, treat December 31, 2027 as a real planning date, not a distant formality. As that date approaches, watch for CMS guidance on what replaces the Bridge, and talk to your prescriber early about contingency options — including whether your specific Wegovy use might qualify under standard Part D coverage rules by that point, or whether manufacturer savings programs make sense as a bridge of your own.
What to Do If You Don't Qualify or Are Denied
Confirm the specific reason for the denial
A denial for "clinical criteria not met" (BMI or comorbidity documentation) needs a different response than a denial because your use is already coverable under standard Part D.
Ask whether your specific use routes to standard Part D instead
If your Wegovy prescription is for cardiovascular risk reduction rather than weight management, the fix isn't a Bridge appeal — it's a standard Part D coverage request through your own plan.
Have your prescriber strengthen the clinical documentation
If the denial cites insufficient BMI or comorbidity evidence, a more complete supporting record — updated weight measurements, documented blood pressure readings, lab values for prediabetes — can support a resubmission.
Look into manufacturer support while you sort out coverage
Novo Nordisk's NovoCare Obesity & Bridge Support team can answer questions specific to Wegovy under this program and may be able to point you toward other savings options if the Bridge doesn't apply to your situation.
Talk to a SHIP counselor if the cost is still a barrier
Your State Health Insurance Assistance Program (SHIP) offers free, unbiased counseling and can help you evaluate whether a different Part D plan, income-based assistance, or a nonprofit prescription assistance program is a better fit if $50 a month is genuinely difficult to afford.
Common Mistakes That Delay Approval
Most delays trace back to routing confusion — sending the right paperwork to the wrong process, or the wrong paperwork to the right one. Confirming which lane applies to your specific prescription before submission avoids the majority of holdups.
Bottom Line
The Wegovy Medicare GLP-1 Bridge program gives eligible beneficiaries a genuinely useful $50 monthly copay for a drug that otherwise lists above $1,000 a month, but it only works for one specific use: chronic weight management, documented through your prescriber's prior authorization submission to a central processor outside your regular Part D plan. If your Wegovy prescription is for cardiovascular risk reduction instead, your standard Part D benefit — not the Bridge — is both the correct and financially better pathway, since that spending counts toward your annual cap.
Because the program is temporary, with an end date of December 31, 2027, and the longer-term replacement model has already faced delays, the smartest move if you're using the Bridge now is to treat the $50 copay as a genuine planning window rather than a permanent fixture — and to start asking what happens next well before the program's final months.
Frequently Asked Questions
The Medicare GLP-1 Bridge is a temporary CMS demonstration program running from July 1, 2026 through December 31, 2027 that lets eligible Medicare Part D beneficiaries get certain GLP-1 medications prescribed for chronic weight management, including Wegovy, at a flat $50 monthly copay. It operates outside your regular Part D benefit rather than as a covered drug on your plan's formulary.
You generally need to be enrolled in a Medicare Part D plan (standalone or through a Medicare Advantage plan with drug coverage), have a BMI of 35 or higher, or a BMI of 27 or higher with a weight-related condition such as hypertension, prediabetes, or cardiovascular disease, and be prescribed Wegovy specifically for chronic weight management rather than for an indication already covered under standard Part D.
No. There is no separate beneficiary enrollment step. Your prescriber submits a prior authorization request on your behalf to the program's designated central claims processor, separate from your regular Part D plan. If approved, you simply pay the $50 copay at a participating pharmacy when you fill the prescription.
No. Because the Bridge program operates outside your standard Part D benefit, the $50 monthly copay does not count toward your Part D deductible or the annual out-of-pocket cap, which is $2,100 in 2026. It also does not receive Extra Help (Low-Income Subsidy) cost-sharing reductions, since those subsidies apply only within the standard Part D benefit.
No. Ozempic is FDA-approved for type 2 diabetes, not chronic weight management, so it is not one of the medications covered under the Bridge program. The Bridge currently covers Wegovy, Zepbound (KwikPen formulation only), and Foundayo, all of which carry an FDA approval specifically for weight management.
The Bridge program is scheduled to run through December 31, 2027. It was designed as a temporary measure ahead of a planned longer-term Medicare model for GLP-1 coverage, though parts of that longer-term rollout have already been delayed. Beneficiaries relying on the Bridge should expect to revisit their coverage options as that end date approaches, since continued $50 pricing isn't guaranteed beyond the program's current end date.
No. Pharmacies don't need to individually opt in to participate in the Bridge program. Once your prior authorization is approved, you can fill your Wegovy prescription at a standard participating retail pharmacy, and the pharmacy bills the program's central processor directly.
No. Enrollment in a Medicare Part D plan, either standalone or bundled into a Medicare Advantage plan with drug coverage, is a baseline requirement for the Bridge program. There is no pathway for Medicare beneficiaries without any Part D coverage.
How We Researched This Guide
References
- Centers for Medicare & Medicaid Services. Medicare Part D Coverage Rules and Demonstration Program Guidance.
- Novo Nordisk. Wegovy Medicare Part D and GLP-1 Bridge Program Information.
- KFF (Kaiser Family Foundation). Analysis of Medicare Part D Enrollment and GLP-1 Coverage Policy.
- Medicare.gov. Official U.S. Government Site for Medicare Benefits and Enrollment.
Suggested additional sources (not embedded — verify before publishing live):
[External Link: CMS's official Medicare GLP-1 Bridge demonstration program announcement page] — omitted because the demonstration launched recently and its permanent public URL structure could not be verified at the time of writing.
[External Link: KFF's specific 2026 brief estimating 3.8 million eligible beneficiaries] — omitted because the exact brief URL could not be independently verified; readers should search KFF's Medicare policy section directly for the most current version.
Related Resources
Related Refill Relay Guides
- [Internal Link: Formulary Exception for Zepbound: How to Request One and Win]
- [Internal Link: Copay Accumulator vs Maximizer — How Each Affects What You Pay]
- [Internal Link: Zepbound vs Wegovy: Coverage, Cost, and Clinical Differences]
- [Internal Link: Can Medicare Patients Use Patient Assistance Programs?]
- [Internal Link: Understanding the 2026 Medicare Part D Out-of-Pocket Cap]
- [Internal Link: Novo Nordisk Patient Assistance Program: 2026 Guide]
- [Internal Link: How to Choose Between Medicare Advantage and Standalone Part D for Specialty Drug Coverage]
Editorial Policy: Refill Relay content is researched using publicly available regulatory materials, manufacturer patient support guidance, and standard Medicare Part D industry practices. Every article is reviewed for clarity, accuracy and usefulness before publication. This content is educational and is not medical or legal advice specific to your individual coverage situation.